Related Experiment Video
Updated: Jun 19, 2026

10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Implementing NICE clinical guidelines on Parkinson's disease
Beverly A Ryton1, B Jane Liddle
1NHS Sheffield.
Clinical Medicine (London, England)
|November 5, 2009
Summary
Implementing national health guidance requires collaboration among healthcare professionals. A successful stakeholder group in Sheffield demonstrates effective engagement for improved patient care pathways.
Area of Science:
- Healthcare Management
- Clinical Implementation Science
- Patient Pathway Optimization
Background:
- National health guidance, such as that from the National Institute for Health and Clinical Excellence (NICE), requires effective implementation by National Health Service (NHS) trusts.
- Successful implementation hinges on cohesive strategies that address the entire patient care pathway.
Purpose of the Study:
- To highlight the importance of interdisciplinary collaboration in implementing national healthcare guidelines.
- To showcase a successful model for engaging diverse stakeholders in healthcare service delivery.
Main Methods:
- Formation of a stakeholder group involving all parties responsible for Parkinson's service provision.
- Focus on collaborative engagement to improve communication and track progress across the care continuum.
Main Results:
- The Sheffield Parkinson's Stakeholder Group successfully engaged all relevant service providers.
- The collaborative approach facilitated a focus on the complete patient care pathway.
- The group's implementation strategy received national recognition.
Conclusions:
- Collaboration across the healthcare community is crucial for the successful implementation of national guidance.
- Engaging all stakeholders ensures comprehensive service improvement and better patient outcomes.
- The Sheffield model provides a replicable framework for effective healthcare implementation.
Related Concept Videos
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
